Krebs Biochemicals & Industries Fair Value
Krebs Biochemicals & Industries (KREBSBIO) average fair value is ₹44.49 across 1 valuation models — Price-to-Sales Valuation, vs a current market price of ₹58.49 (-23.94%), fair value range ₹44.49–₹44.49. Check KREBSBIO company valuation to track the company's total market size over time.
Fair Value Analysis Export
KREBSBIO Fair Value vs Current Price — Valuation Summary
KREBSBIO average fair value, fair value range, price gap and valuation status across 1 models: Price-to-Sales Valuation.
Price-to-Sales Valuation
KREBSBIO Fair Value Analysis — Data Sources & Coverage
Krebs Biochemicals & Industries financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit Krebs Biochemicals & Industrie screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
KREBSBIO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Krebs Biochemicals & Industries P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Sat Kartar Life | SATKARTAR | 13.44 | 3.4 | ₹226 |
| KRM Ayurveda | KRMAYURVED | - | 4.56 | ₹545 |
| Emcure Pharmaceuticals | EMCURE | 37.24 | 7.08 | ₹34,821 |
| SMS Lifesciences | SMSLIFE | 22.27 | 1.82 | ₹354 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.